In recent years, the immunoderivative (IMiD) agents have been extensively used for the treatment of multiple myeloma (MM). IMiDs and their newer derivatives CRBN E3 ligase modulator bind the E3 ligase substrate recognition adapter protein cereblon (CRBN), which has been recognized as one of the IMiDs’ direct target proteins, and it is essential for the therapeutic effect of these agents. High expression of CRBN was associated with improved clinical response in patients with MM treated with IMiDs, further confirming that the expression of IMiDs’ direct target protein CRBN is required for the anti-MM activity. CRBN’s central role as a target of IMiDs suggests potential utility as a predictive biomarker of response or resistance to IMiDs therapy. Additionally, the presence of alternatively spliced variants of CRBN in MM cells, especially those lacking the drug-binding domain for IMiDs, raise questions concerning their potential biological function, making difficult the transcript measurement, which leads to inaccurate overestimation of full-length CRBN transcripts. In sight of this, in the present study, we evaluated the CRBN expression, both full-length and spliced isoforms, by using real-time assay data from 87 patients and RNA sequencing data from 50 patients (n = 137 newly diagnosed MM patients), aiming at defining CRBN’s role as a predictive biomarker for response to IMiDs-based induction therapy. We found that the expression level of the spliced isoform tends to be higher in not-responding patients, confirming that the presence of a more CRBN spliced transcript predicts for lack of IMiDs response.

Borsi E., Mazzocchetti G., Dico A.F., Vigliotta I., Martello M., Poletti A., et al. (2023). High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients. CLINICAL AND EXPERIMENTAL MEDICINE, 23(8), 5227-5239 [10.1007/s10238-023-01205-y].

High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients

Borsi E.;Mazzocchetti G.;Vigliotta I.;Martello M.;Poletti A.;Solli V.;Armuzzi S.;Taurisano B.;Kanapari A.;Pistis I.;Zamagni E.;Tacchetti P.;Pantani L.;Mancuso K.;Rocchi S.;Rizzello I.;Cavo M.;Terragna C.
2023

Abstract

In recent years, the immunoderivative (IMiD) agents have been extensively used for the treatment of multiple myeloma (MM). IMiDs and their newer derivatives CRBN E3 ligase modulator bind the E3 ligase substrate recognition adapter protein cereblon (CRBN), which has been recognized as one of the IMiDs’ direct target proteins, and it is essential for the therapeutic effect of these agents. High expression of CRBN was associated with improved clinical response in patients with MM treated with IMiDs, further confirming that the expression of IMiDs’ direct target protein CRBN is required for the anti-MM activity. CRBN’s central role as a target of IMiDs suggests potential utility as a predictive biomarker of response or resistance to IMiDs therapy. Additionally, the presence of alternatively spliced variants of CRBN in MM cells, especially those lacking the drug-binding domain for IMiDs, raise questions concerning their potential biological function, making difficult the transcript measurement, which leads to inaccurate overestimation of full-length CRBN transcripts. In sight of this, in the present study, we evaluated the CRBN expression, both full-length and spliced isoforms, by using real-time assay data from 87 patients and RNA sequencing data from 50 patients (n = 137 newly diagnosed MM patients), aiming at defining CRBN’s role as a predictive biomarker for response to IMiDs-based induction therapy. We found that the expression level of the spliced isoform tends to be higher in not-responding patients, confirming that the presence of a more CRBN spliced transcript predicts for lack of IMiDs response.
2023
Borsi E., Mazzocchetti G., Dico A.F., Vigliotta I., Martello M., Poletti A., et al. (2023). High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients. CLINICAL AND EXPERIMENTAL MEDICINE, 23(8), 5227-5239 [10.1007/s10238-023-01205-y].
Borsi E.; Mazzocchetti G.; Dico A.F.; Vigliotta I.; Martello M.; Poletti A.; Solli V.; Armuzzi S.; Taurisano B.; Kanapari A.; Pistis I.; Zamagni E.; T...espandi
File in questo prodotto:
File Dimensione Formato  
s10238-023-01205-y.pdf

accesso aperto

Descrizione: versione editoriale
Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 2.36 MB
Formato Adobe PDF
2.36 MB Adobe PDF Visualizza/Apri
10238_2023_1205_MOESM1_ESM.docx

accesso aperto

Descrizione: dati supplementari
Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 30.27 kB
Formato Microsoft Word XML
30.27 kB Microsoft Word XML Visualizza/Apri
10238_2023_1205_MOESM2_ESM.docx

accesso aperto

Descrizione: dati supplementari
Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 13.2 kB
Formato Microsoft Word XML
13.2 kB Microsoft Word XML Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/959912
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact